

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-24. Cancelled

25. (Currently amended) A microemulsion composition for intravenous delivery comprising an oil phase and an aqueous phase, wherein the oil phase ~~consists essentially of~~ comprises:

an oil-soluble drug;

a long chain polymer surfactant component, wherein the long chain polymer surfactant component is a polymer surfactant having a molecular weight greater than 1000; and

a short chain fatty acid surfactant component;

wherein the oil phase is free of a carrier of the oil-soluble drug and

wherein the amounts of the long chain polymer and short chain fatty acid surfactant components are selected to provide for spontaneous formation of thermodynamically stable microemulsion droplets of the oil phase having a particle size from 10nm to 100nm.

26. (Cancelled)

27. (Previously presented) The composition of claim 25, wherein the long chain polymer surfactant component is selected from the group consisting of polyoxyethylene alkyl esters, polyoxyethylene glycols, polyvinylpyrrolidone, polyvinylalcohol, tyloxapol, and poloxamer.

28. (Previously presented) The composition of claim 27, wherein the long chain polymer surfactant component is a poloxamer.

29. (Previously presented) The composition of claim 25, wherein the short chain fatty acid surfactant component is a C<sub>8</sub> to C<sub>16</sub> component.

30. (Previously presented) The composition of claim 29, wherein the short chain fatty acid surfactant component is a C<sub>8</sub> to C<sub>12</sub> component.

31. (Previously presented) The composition of claim 25, wherein the long chain polymer surfactant component is a poloxamer and the short chain fatty acid surfactant component is a laurate.

32. (Previously presented) The composition of claim 25, wherein the total amount of long chain polymer surfactant component and short chain fatty acid surfactant component does not exceed 4.65 % by weight.

33. (Previously presented) The composition of claim 25, wherein the interfacial tension of the oil-soluble drug with an emulsifier combination comprising the long chain polymer surfactant component and the short chain fatty acid surfactant component is less than 0.1 dynes per cm.

34. (Previously presented) The composition of claim 25, wherein the oil-soluble drug is selected from the group consisting of analgesics, anesthetics, antibiotics, antidepressants, antidiabetics, antifungals, antihypertensives, anti-inflammatories, antineoplastics, immunosuppressives, sedatives, antianginals, antipsychotics, antimanics, antiarthritics, antigouts, anticoagulants, antithrombolytics, anticonvulsants, antiparkinsons, antibacterials, antivirals, and anti-infectives.

35. (Previously presented) The composition of claim 34, wherein the oil-soluble drug is an anesthetic.

36. (Previously presented) The composition of claim 35, wherein the oil-soluble drug is an aryl containing molecule.

37. (Previously presented) The composition of claim 25, wherein the oil-soluble drug is an oil-soluble vitamin.

38. (Previously presented) The composition of claim 25, wherein the long chain polymer surfactant component and the short chain fatty acid surfactant component are suitable for intravenous or oral administration to a human patient.

39. (Previously presented) The composition of claim 25, wherein the ratio of long chain polymer surfactant component to short chain fatty acid surfactant component is from 10:100 to 25:80 wt/wt.

40. (Previously presented) The composition of claim 25, wherein the long chain polymer surfactant component has a molecular weight greater than 1000, and the short chain fatty acid surfactant component has a molecular weight less than 1000.

41. (Previously presented) The composition of claim 39, wherein the amount of oil-soluble drug is from 0.1% to 1.0%.

42. (Previously presented) The composition of claim 25, wherein the oil-soluble drug is a mixture of the base form and the salt form of the drug.

43. (Previously presented) The composition of claim 25, wherein the drug transfer rate is controlled by control of the character and nature of micelle formation of the microemulsion droplets.

44. (Cancelled)

45. (Currently amended) A microemulsion composition for drug delivery comprising an oil phase and an aqueous phase, wherein the oil phase ~~consists essentially of~~ comprises:

an oil-soluble drug; and

an emulsifier combination comprising a long chain polymer surfactant component and a short chain fatty acid surfactant component; wherein the long chain polymer surfactant component is a polymer surfactant having a molecular weight greater than 1000, wherein the emulsifier combination is free of a carrier of the oil-soluble drug;

and wherein the amounts of the long chain polymer surfactant component and the short chain fatty acid surfactant component are selected to provide for spontaneous formation of thermodynamically stable microemulsion droplets of the oil phase having a particle size from 10nm to 100nm and wherein the interfacial tension of the oil-soluble drug with the emulsifier combination is less than 0.1 dynes per cm.

46. (Cancelled)

47. (Previously presented) The microemulsion composition of claim 25 comprising at least two oil-soluble drugs.

48. (New) The microemulsion of claim 35, wherein the anesthetic is 2, 6-diisopropylphenol.